<div class="headers"><div>Figure 2 (facing page). Percentage of Patients in the ENACT-1 Trial with a Clinical Response at Each Visit (Panel A), in Remission at Each Visit (Panel B), with a Response at Week 10 (Panel C), and in Remission at Week 10 (Panel D).A response was defined as a decrease from baseline in the CDAI score of at least 70 points. Remission was de-fined as a decrease in the CDAI score to less than 150 points. Significant differences between the treatment groups are shown.</div></div><table class='gmisc_table' style='border-collapse: collapse; margin-top: 1em; margin-bottom: 1em;' >
<tbody>
<tr style='border-top: 2px solid grey;'>
<td style='border-top: 2px solid grey; text-align: left;'><p style="" class="">Figure 2 (facing page). Percentage of Patients in the ENACT-1 Trial with a Clinical Response at Each Visit (Panel A), in Remission at Each Visit (Panel B), with a Response at Week 10 (Panel C), and in Remission at Week 10 (Panel D).</p></td>
</tr>
<tr>
<td style='border-bottom: 2px solid grey; text-align: left;'><p style="" class="">A response was defined as a decrease from baseline in the CDAI score of at least 70 points. Remission was de-fined as a decrease in the CDAI score to less than 150 points. Significant differences between the treatment groups are shown.</p></td>
</tr>
</tbody>
</table>
